Zobrazeno 1 - 10
of 138
pro vyhledávání: ''
Autor:
Jinying Shen, Yujie Zhao, Linhai Zhong, Tianhui Hu, Xiong Chen, Xiaolin Xu, Daxuan Wang, Yan-yan Zhan, Xiaoting Hong, Hanwei Cao, Yitong Zhou, Jianben Wu, Ying Lin, Wenqing Zhang, Jihuan Hou
Publikováno v:
Cancer Research. 81:5904-5918
Invasive mucinous lung adenocarcinoma (IMA) is a subtype of lung adenocarcinoma with a strong invasive ability. IMA frequently carries "undruggable" KRAS mutations, highlighting the need for new molecular targets and therapies. Nuclear receptor HNF4
Autor:
Cory Abate-Shen, Amir Lankarani, Matteo Di Bernardo, Michael M. Shen, Rivka L. Shoulson, Soonbum Park, Lijie Rong, Tomasz Owczarek, Talal Syed, Hikmat Al-Ahmadie, David B. Solit, James M. McKiernan, Chee-Wai Chua, Prithi Chakrapani, Jaime Y. Kim
Publikováno v:
Cancer Res
To study the progression of bladder cancer from non–muscle-invasive to muscle-invasive disease, we have developed a novel toolkit that uses complementary approaches to achieve gene recombination in specific cell populations in the bladder urotheliu
Autor:
Bruce A. Littlefield, Elodie Modave, Amy Weaver, Bram Boeckx, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 27:3106-3115
Purpose:A randomized phase III study evaluated the efficacy of eribulin versus dacarbazine in patients with advanced liposarcoma and leiomyosarcoma. Improved overall survival (OS) led to approval of eribulin for liposarcoma, but not for leiomyosarcom
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Kristan H. Cleveland, Abdullah Shamim, Sherry Liang, Ying Huang, Mengbing Chen, Cyrus Parsa, Bradley T. Andresen, Ayaz Shahid, Robert Orlando
Publikováno v:
Cancer Prev Res (Phila)
Skin cancer is the most common malignancy worldwide and is rapidly rising in incidence, representing a significant public health challenge. The β-blocker, carvedilol, has shown promising effects in preventing skin cancer. However, as a potent β-blo
Autor:
Peter S. Hammerman, Jing Yuan, Lesley A. Mathews Griner, Peter Aspesi, Daniel J. McKay, Gwynn Pardee, Hui Qin Wang, Kelli-Ann Monaco, Ribo Guo, Kenneth Crawford, Stephania Widger, Darrin Stuart, Vesselina G. Cooke, Karen Bui, Felipa A. Mapa, Yuji Mishina, Mariela Jaskelioff, Jeffrey A. Engelman, Paul Fordjour, Emma Labrot, Giordano Caponigro, Stacy Higgins, Jessi Ambrose, John Fuller, Jinsheng Liang, John Green, Scott Delach
Publikováno v:
Clinical Cancer Research. 27:2061-2073
Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. Experimental Design: LXH254 was profiled in biochemical, in vitro, and in vivo assay
Autor:
Douglas R. Spitz, Vishnu Menon, Kevin Cho, Michael C. Zahner, Yuting Wang, Naoshad Muhammad, Jin Zhang, Ramachandran Rashmi, Julie K. Schwarz, Xiaojing Huang, Buck E. Rogers, Gary J. Patti, Sisi Zhang, Yi Huang, Michael L. McCormick, Kay Jayachandran, Fiona Ruiz
Publikováno v:
Mol Cancer Ther
The purpose of this study was to determine if radiation (RT)-resistant cervical cancers are dependent upon glutamine metabolism driven by activation of the PI3K pathway and test whether PI3K pathway mutation predicts radiosensitization by inhibition
Autor:
Amy Zhang, Grainne M. O'Kane, Paz Polak, Celia M. T. Greenwood, James Joseph Biagi, Sandra Fischer, Julie M. Wilson, Louis-Martin Boucher, Gun Ho Jang, Zu-Hua Gao, Jennifer J. Knox, Yifan Wang, Yasser Riazalhosseini, Nathaniel Bouganim, Ayelet Borgida, David Valenti, Robert C. Grant, Steven Gallinger, Mehdi Masoomian, Robert E. Denroche, William D. Foulkes, John M. S. Bartlett, Chani Stossel, Maria Raitses-Gurevich, Alain Pacis, Ilinca Lungu, Talia Golan, Simeng Bu, Jean Monlong, T. Cabrera, George Zogopoulos, Celine Domecq, Spring Holter, Jin Yong Patrick Park, Jamil Asselah, Adeline Cuggia
Publikováno v:
WAng, Y, Patrick Park, J Y, Pacis, A, E. Denroche, R, Jang, G H, Zhang, A, Cuggia, A, Domecq, C, Monlong, J, Raitses-Gurevich, M, C. Grant, R, Borgida, A, Holter, S, Stossel, C, Bu, S, Masoomian, M, Lungu, I, Bartlett, J, M. Wilson, J, Gao, Z-H, Riazalhosseini, Y, Asselah, J, Bouganim, N, Cabrera, T, Boucher, L-M, Valenti, D, Biagi, J, M.T Greenwood, C, Polak, P, D. Foulkes, W, Golan, T, M. O'Kane, G, E. Fischer, S, J. Knox, J, Gallinger, S & Zogopoulos, G 2020, ' A preclinical trial and molecularly-annotated patient cohort identify predictive biomarkers in homologous recombination deficient pancreatic cancer ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-20-1439
Purpose:Pancreatic ductal adenocarcinoma (PDAC) arising in patients with a germline BRCA1 or BRCA2 (gBRCA) mutation may be sensitive to platinum and PARP inhibitors (PARPi). However, treatment stratification based on gBRCA mutational status alone is
Publikováno v:
Cancer Research. 80:3945-3958
Malignant glioma constitutes one of the fatal primary brain tumors in adults. Such poor prognosis calls for a better understanding of cancer-related signaling pathways of this disease. Here we elucidate a MYC-miRNA-MXI1 feedback loop that regulates p
Autor:
Richard Price, Christine Ju, Johanna C. Bendell, Herbert Hurwitz, Xiaoju Max Ma, John Lee, Nalin Tikoo, Christoph Mancao, Lijing Yao, Alex Lovejoy, Alan Nicholas, Stephanie J. Yaung, John F. Palma, Nicolas Sommer
Publikováno v:
Clinical Cancer Research. 26:4010-4017
Purpose:We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.Experimental Design:The Sequencing Triplet With Avastin and Mai